- Home
- RARE vs WD Comparison
RARE vs WD Comparison
Compare RARE & WD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RARE | WD |
|---|---|---|
| Founded | 2010 | 1937 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.1B |
| IPO Year | 2013 | 2010 |
Fundamental Metrics
Financial Performance| Metric | RARE | WD |
|---|---|---|
| Price | $23.18 | $45.15 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 19 | 3 |
| Target Price | $66.32 | ★ $83.33 |
| AVG Volume (30 Days) | ★ 2.1M | 250.5K |
| Earning Date | 05-04-2026 | 05-29-2026 |
| Dividend Yield | N/A | ★ 5.65% |
| EPS Growth | ★ 7.31 | N/A |
| EPS | N/A | ★ 1.64 |
| Revenue | $673,000,000.00 | ★ $1,234,306,000.00 |
| Revenue This Year | $17.23 | $21.20 |
| Revenue Next Year | $36.13 | $10.20 |
| P/E Ratio | ★ N/A | $23.17 |
| Revenue Growth | ★ 20.13 | 8.99 |
| 52 Week Low | $18.41 | $46.53 |
| 52 Week High | $43.22 | $90.00 |
Technical Indicators
Market Signals| Indicator | RARE | WD |
|---|---|---|
| Relative Strength Index (RSI) | 48.43 | 22.33 |
| Support Level | $22.00 | N/A |
| Resistance Level | $25.46 | $66.25 |
| Average True Range (ATR) | 1.29 | 2.93 |
| MACD | 0.25 | -1.73 |
| Stochastic Oscillator | 72.03 | 15.18 |
Price Performance
Historical ComparisonAbout RARE Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.
About WD Walker & Dunlop Inc
Walker & Dunlop Inc is a United States-based commercial real estate finance company. It is principally engaged in originating, selling, and servicing a number of multifamily and other commercial real estate financing products that are sold under the programs of Freddie Mac, Fannie Mae, Ginnie Mae, and the Federal Housing Administration. The company is managed based on three reportable segments: Capital Markets (CM), Servicing & Asset Management (SAM), and Corporate. The company generates a majority of total revenue from gains from mortgage banking activities and servicing fees. It conducts business solely in the United States.